Tier 4 — mechanistic

Enzymatically Modified Isoquercitrin: Production, Metabolism, Bioavailability, Toxicity, Pharmacology, and Related Molecular Mechanisms

Aleksandra Owczarek-Januszkiewicz, Anna Magiera, Monika Anna Olszewska
International journal of molecular sciences 2022 23(23):14784

Bibliography

PubMed
PMID 36499113
PubMed Central
PMC9738368
DOI
10.3390/ijms232314784
Funding
Indexed grant support: 503/3-022-01/503-31-001 — Medical University of Lodz. The indexed list may not contain the complete funding declaration.
Competing interests
Reported disclosure: The authors declare no conflict of interest.

Study snapshot

DesignNarrative review of enzymatically modified isoquercitrin
ModelNarrative or mixed evidence review
SampleMetabolism, toxicity, and pharmacology literature; no new clinical cohort
InterventionEMIQ and related quercetin glycosides
DurationLiterature available at publication
EndpointsExposure and pharmacokinetics

What the study showed, in plain terms

Published in 2022, this source examined forms, absorption and food sources. Its evidence base was Metabolism, toxicity, and pharmacology literature; no new clinical cohort. It evaluated EMIQ and related quercetin glycosides across Literature available at publication.

The review describes improved aqueous properties and absorption alongside experimental pharmacology and safety findings.

A modified glycoside is not interchangeable with aglycone or every phytosome. Better absorption does not establish superior long-term health outcomes.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Forms: Dihydrate, Phytosome, Liposomal and Glycosides. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • The review describes improved aqueous properties and absorption alongside experimental pharmacology and safety findings.
  • The recorded outcome domains were Exposure and pharmacokinetics.

What this study can and cannot tell us

  • A modified glycoside is not interchangeable with aglycone or every phytosome. Better absorption does not establish superior long-term health outcomes.
  • The conclusions inherit the limitations of the underlying studies. A narrative interpretation or guideline recommendation is not a new randomized treatment comparison.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Improving quercetin bioavailability: A systematic review and meta-analysis of human intervention studies
Lu Liu et al. · Food chemistry · 2025
Tier 4
A critical examination of human data for the biological activity of quercetin and its phase-2 conjugates
Gary Williamson et al. · Critical reviews in food science and nutrition · 2025
Tier 4
Recent advances on the improvement of quercetin bioavailability
Kevser Kandemir et al. · Trends in Food Science & Technology · 2022
Tier 2
Bioavailability of Quercetin in Humans with a Focus on Interindividual Variation
A Filipa Almeida et al. · Comprehensive reviews in food science and food safety · 2018

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology